ArticleFrontiers in immunology2012
Podoplanin: emerging functions in development, the immune system, and cancer.
Article in Frontiers in immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 239 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
239 citing papers in PubMed, 4 syntheses or guidelines pooled it, 396 citations in OpenAlex.
- Angiosarcoma: a systematic review of biomarkers in diagnosis, prognosis, and therapeutic strategies.Frontiers in oncology · 2025Pooled it
- Pooled it
- Clinical and Molecular Features of Morpheaform Basal Cell Carcinoma: A Systematic Review.Current oncology (Toronto, Ont.) · 2023Pooled it
- Pooled it
- Podoplanin-positive extracellular vesicles in ovarian cancer: linking thrombosis, platelet crosstalk, and cancer stemness - a narrative review.Annals of medicine and surgery (2012) · 2026Article
- Corpora amylacea and glymphatic system in temporal lobe epilepsy patients: Clinicopathological correlation.Epilepsia · 2026Article
- Molecular control of platelet extravasation into tumors and its impact on tumor growth.Blood vessels, thrombosis & hemostasis · 2026Article
- Modeling Tay-Sachs Disease in Astrocyte-like Cells Reveals Significant Changes in the Transcriptomic Profile.International journal of molecular sciences · 2026Article
- Novel CAR T cell blend targeting PDPN and GD2 to overcome glioblastoma heterogeneity.Journal for immunotherapy of cancer · 2026Article
- Single Cell Transcriptomics and Surface Protein Expression Reveal Distinct Cellular and Molecular Phenotypes in Human RPESC-RPE and PSC-RPE.bioRxiv : the preprint server for biology · 2026Article
- Metabolic Syndrome-Driven Changes in Cardiac Lymphatic Endothelium: mRNA Expression and Emerging Questions.Pathophysiology : the official journal of the International Society for Pathophysiology · 2026Article
- Circulating tumor cells and circulating tumor microemboli: role in venous thromboembolism in oncologic patients.Bioscience reports · 2026Review
- Diagnostic Value of Serum and Salivary Podoplanin as Clinical Biomarkers for Distinguishing Oral Cancer from Oral Leukoplakia.Diagnostics (Basel, Switzerland) · 2026Article
- Misdiagnosed undifferentiated pleomorphic sarcoma of the right lower leg mimicking atypical fibroxanthoma: a case report and literature review.Frontiers in oncology · 2026Article
- Immunotherapy resistance and strategies in malignant pleural mesothelioma.Cancer drug resistance (Alhambra, Calif.) · 2026Review
- Transcriptomics-guided serum podoplanin and interpretable machine learning for early risk stratification of necrotizing enterocolitis in preterm infants.Frontiers in immunology · 2026Article
- Melanoma and its fibroblastic allies: the emerging importance of CAFs in immune suppression, ECM modulation, and therapy resistance.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Engineered macroporous gelatin scaffolds enhance lymph node fibroblastic reticular cell identity and enable diabetogenic T cell immunomodulation.Biomaterials · 2026Article
- Paired single cell analysis reveals chemotherapy resistance in osteosarcoma.Cancer drug resistance (Alhambra, Calif.) · 2026Article
- Integrative analysis identifies LHFPL6 as a CAF-specific prognostic biomarker in colorectal cancer.Clinical and experimental medicine · 2025Article
179 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Podoplanin (PDPN) is a well-conserved, mucin-type transmembrane protein expressed in multiple tissues during ontogeny and in adult animals, including the brain, heart, kidney, lungs, osteoblasts, and lymphoid organs. Studies of PDPN-deficient mice have demonstrated that this molecule plays a critical role in development of the heart, lungs, and lymphatic system. PDPN is widely used as a marker for lymphatic endothelial cells and fibroblastic reticular cells of lymphoid organs and for lymphatics in the skin and tumor microenvironment. Much of the mechanistic insight into PDPN biology has been gleaned from studies of tumor cells; tumor cells often upregulate PDPN as they undergo epithelial-mesenchymal transition and this upregulation is correlated with increased motility and metastasis. The physiological role of PDPN that has been most studied is its ability to aggregate and activate CLEC-2-expressing platelets, as PDPN is the only known endogenous ligand for CLEC-2. However, more recent studies have revealed that PDPN also plays crucial roles in the biology of immune cells, including T cells and dendritic cells. This review will provide a comprehensive overview of the diverse roles of PDPN in development, immunology, and cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.